NL
DE
Osteoarthritis is one of the leading causes of disability in Europe and the US. The Trammpolin meniscus is an implant that aims at reducing knee pain and improve mobility. The focus of the Breakthrough Device Designation program is to accelerate access for patients and caregivers to effective medical innovation. The meniscus implant will receive priority in upcoming FDA evaluations.
Related news items
ATRO Medical starts unique meniscus study
1 November 2024As the first worldwide, ATRO Medical is starting a clinical study on the function of an artificial outer meniscus, the lateral meniscus. This is a first: never before has a removed lateral meniscus been replaced by a plastic specimen, the Artimis® Meniscus Prosthesis.
read more
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
EU grant awarded to development of meniscus prosthesis € 2.5 million for ATRO Medical
8 June 2022 The Dutch startup works on the first anatomical meniscus prostheses for patients with chronic knee pain. Their ground-breaking innovation continues to attract international attention, paving the way towards full-scale healthcare implementation. read more
ATRO Medical closes a new financing round for the Trammpolin® meniscus prosthesis
17 December 2021 ATRO Medical announces the successful closure of a €1.9 million financing round to complete the AIR2 clinical study. read more
